B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes

Journal of the American Heart Association

Volumn 3, Issue 3, 2014, Pages

  Flint, Kelsey M ^a   Allen, Larry A ^b,c   Pham, Michael ^a,d   Heidenreich, Paul A ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Department of Medicine   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Heart failure; Natriuretic peptides; Patient readmission; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; BLOOD; EPIDEMIOLOGY; HOSPITAL ADMISSION; PUBLIC HOSPITAL; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; FEMALE; HEART FAILURE; HOSPITALS, VETERANS; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT ADMISSION; PATIENT DISCHARGE; PATIENT READMISSION; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84913566627     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000806     Document Type: Article

References (40)

1. Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, Peterson ED, Curtis LH. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303:1716-1722.
2. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418-1428.
3. Allen LA, Tomic KES, Smith DM, Wilson KL, Agodoa I. Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure. Circ Heart Fail. 2012;5: 672-679.
4. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309:355-363.
5. Ross JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, Krumholz HM. Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med. 2008;168:1371-1386.
6. Zaya M, Phan A, Schwarz ER. Predictors of re-hospitalization in patients with chronic heart failure. World J Cardiol. 2012;4:23-30.
7. Hernandez MB, Schwartz RS, Asher CR, Navas EV, Totfalusi V, Buitrago I, Lahoti A, Novaro GM. Predictors of 30-day readmission in patients hospitalized with decompensated heart failure. Clin Cardiol. 2013;36:542-547.
8. Kim H-N, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015-2019.
9. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
10. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
11. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R; Rapid Emergency Department Heart Failure Outpatient Trial Investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328-1333.
12. Michtalik HJ, Yeh H-C, Campbell CY, Haq N, Park H, Clarke W, Brotman DJ. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol. 2011;107:1191-1195.
13. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641.
14. Faggiano P, Valle R, Aspromonte N, D'Aloia A, di Tano G, Barro S, Giovinazzo P, Milani L, Lorusso R, Dei Cas L. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification. Int J Cardiol. 2010;140:88-94.
15. Valle R, Aspromonte N, Giovinazzo P, Carbonieri E, Chiatto M, di Tano G, Feola M, Milli M, Fontebasso A, Barro S, Bardellotto S, Milani L. B-type natriuretic peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. J Card Fail. 2008;14:219-224.
16. Valle R, Prevaldi C, D'Eri A, Fontebasso A, Giovinazzo P, Noventa F, Barro S, Carbonieri E, Milani L, Aspromonte N. B-type natriuretic peptide predicts postdischarge prognosis in elderly patients admitted due to cardiogenic pulmonary edema. Am J Geriatr Cardiol. 2006;15:202-207.
17. Feola M, Aspromonte N, Canali C, Ceci V, Giovinazzo P, Milani L, Quarta G, Ricci R, Scardovi AB, Uslenghi E, Valle R. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients > 70 years of age with heart failure. AJC. 2005;96:705-709.
18. Pimenta J, Paulo C, Mascarenhas J, Gomes A, Azevedo A, Rocha-Goncálves F, Bettencourt P. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol. 2010;145:209-214.
19. Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek J, Bozkurt B. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009;15:293-299.
20. Cournot M, Leprince P, Destrac S, Ferriéres J. Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am J Geriatr Cardiol. 2007;16:8-14.
21. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. Nterminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174.
22. Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E, Ballarino P, Semplicini A, Bertazzoni G, Carpinteri G, Mulè P, Pazzaglia M, Shah K, Maisel A, Clopton P. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care. 2010;14:R116.
23. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
24. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M; ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943-1950.
25. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52:997-1003.
26. Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O'Connor CM, Felker GM, Hernandez AF. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes. Circ Heart Fail. 2011;4:628-636.
27. Savarese G, Musella F, D'Amore C, Vasello E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure. JACC Heart Fail. 2014;2:148-158.
28. Cook NR, Ridker PM. The use and magnitude of reclassification measures for individual predictors of global cardiovascular risk. Ann Intern Med. 2009;150: 795-802.
29. Dokainish H, Zoghbi WA, Lakkis NM, Al-Bakshy F, Dhir M, Quinones MA, Nagueh SF. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation. 2004;109:2432-2439.
30. Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J. 2004;148:895-902.
31. Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani L. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005;11:498-503.
32. Valle R, Aspromonte N, Carbonieri E, D'Eri A, Feola M, Giovinazzo P, Noventa F, Prevaldi C, Barro S, Milani L. Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol. 2008;126:400-406.
33. Noveanu M, Breidthardt T, Potocki M, Reichlin T, Twerenbold R, Uthoff H, Socrates T, Arenja N, Reiter M, Meissner J, Heinisch C, Stalder S, Mueller C. Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short-and long-term outcome in acute decompensated heart failure. Crit Care. 2011;15:R1.
34. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol. 2009;53:2343-2348.
35. Luchner A, Möckel M, Spanuth E, Möcks J, Peetz D, Baum H, Spes C, Wrede CE, Vollert J, Müller R, Katus H, Giannitsis E. N-terminal pro brain natriuretic peptide in the management of patients in the medical emergency department (PROMPT): correlation with disease severity, utilization of hospital resources, and prognosis in a large, prospective, randomized multicentre trial. Eur J Heart Fail. 2012;14:259-267.
36. Norton C, Georgiopoulou VV, Kalogeropoulos AP, Butler J. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54:78-85.
37. Mechanic R, Tompkins C. Lessons learned preparing for Medicare bundled payments. N Engl J Med. 2012;367:1873-1875.
38. Cutler DM, Ghosh K. The potential for cost savings through bundled episode payments. N Engl J Med. 2012;366:1075-1077.
39. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Maisel AS. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151:999-1005.
40. van Veldhuisen DJ, Linssen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JGP, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498-1506.